Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQ for the Treatment of Childhood Brain Cancer (GlobeNewswire) - Jun 25, 2025 - "Plus Therapeutics, Inc...announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application (No. 168178) for REYOBIQ (Rhenium Re186 Obisbemeda) for the treatment of pediatric patients with supratentorial recurrent, refractory, or progressive high-grade glioma (HGG) and ependymoma. The trial will be referred to as the ReSPECT-PBC trial and is funded by a $3.0M research grant from the U.S. Department of Defense."
Financing • IND • Ependymoma • High Grade Glioma
|